| 1 |
34871917 | Quantification of the janus kinase 1 inhibitor upadacitinib in human plasma by LC-MS/MS. | 2022 Jan 1 |
2 |
| 2 |
35014922 | Evaluating upadacitinib for the treatment of psoriatic arthritis. | 2022 Feb |
1 |
| 3 |
35224383 | Unraveling the Molecular Mechanism of Recognition of Selected Next-Generation Antirheumatoid Arthritis Inhibitors by Janus Kinase 1. | 2022 Feb 22 |
2 |
| 4 |
35267240 | Response of rheumatoid arthritis-associated pyoderma gangrenous to the JAK1 inhibitor upadacitinib. | 2022 Apr |
1 |
| 5 |
35437207 | An epidermal keratinocyte homogenate induced type 2 and proinflammatory cytokine expression in cultured dermal cells. | 2022 May |
1 |
| 6 |
35446502 | Ansprechen eines mit rheumatoider Arthritis assoziierten Pyoderma gangraenosum auf den JAK1-Inhibitor Upadacitinib. | 2022 Apr |
1 |
| 7 |
32648334 | Characterization of the Effect of Upadacitinib on the Pharmacokinetics of Bupropion, a Sensitive Cytochrome P450 2B6 Probe Substrate. | 2021 Mar |
1 |
| 8 |
33129109 | Enhanced efficacy of JAK1 inhibitor with mTORC1/C2 targeting in smoldering/chronic adult T cell leukemia. | 2021 Jan |
1 |
| 9 |
33156550 | Exposure-Response Analyses for Upadacitinib Efficacy in Subjects With Atopic Dermatitis-Analyses of Phase 2b Study to Support Selection of Phase 3 Doses. | 2021 May |
1 |
| 10 |
33354610 | Bridging to a selective Janus kinase 1 inhibitor in severe atopic dermatitis: An instructive case with upadacitinib. | 2021 Jan |
1 |
| 11 |
33527177 | Upadacitinib in Rheumatoid Arthritis: A Benefit-Risk Assessment Across a Phase III Program. | 2021 May |
1 |
| 12 |
33741556 | JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib. | 2021 Jul |
1 |
| 13 |
33755884 | Quality of Life and Work Productivity Improvements with Upadacitinib: Phase 2b Evidence from Patients with Moderate to Severe Crohn's Disease. | 2021 May |
1 |
| 14 |
33909185 | JAK Inhibitors for Axial Spondyloarthritis: What does the Future Hold? | 2021 Apr 28 |
1 |
| 15 |
33950225 | Phase III trials of JAK1 selective inhibitors in rheumatoid arthritis. | 2021 May 5 |
1 |
| 16 |
33950228 | Early phase studies of JAK1 selective inhibitors in rheumatoid arthritis. | 2021 May 5 |
2 |
| 17 |
33950230 | The safety of JAK-1 inhibitors. | 2021 May 5 |
1 |
| 18 |
33950231 | Clinical use of Jak 1 inhibitors for rheumatoid arthritis. | 2021 May 5 |
1 |
| 19 |
34023008 | Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. | 2021 Jun 5 |
1 |
| 20 |
34023009 | Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. | 2021 Jun 5 |
1 |
| 21 |
34042156 | Randomized Controlled Trial Substudy of Cell-specific Mechanisms of Janus Kinase 1 Inhibition With Upadacitinib in the Crohn's Disease Intestinal Mucosa: Analysis From the CELEST Study. | 2021 Nov 15 |
2 |
| 22 |
34471993 | Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors. | 2021 Oct |
3 |
| 23 |
34514265 | A Novel Scalarized Scaffold Hopping Algorithm with Graph-Based Variational Autoencoder for Discovery of JAK1 Inhibitors. | 2021 Sep 7 |
2 |
| 24 |
34532638 | Janus kinase inhibitors for the therapy of atopic dermatitis. | 2021 |
1 |
| 25 |
34629864 | Development of an UPLC-MS/MS Method for the Quantitative Analysis of Upadacitinib in Beagle Dog Plasma and Pharmacokinetics Study. | 2021 |
2 |
| 26 |
34645316 | Use of upadacitinib in the treatment of psoriatic arthritis. | 2021 Dec |
1 |
| 27 |
34659493 | The role of upadacitinib in the treatment of moderate-to-severe active rheumatoid arthritis. | 2021 |
1 |
| 28 |
34761860 | Alleviation of erosive oral and esophageal lichen planus by the JAK1 inhibitor upadacitinib. | 2021 Dec |
1 |
| 29 |
34894197 | Besserung eines oralen und ösophagealen Lichen ruber mucosae unter dem JAK1-Inhibitor Upadacitinib. | 2021 Dec |
1 |
| 30 |
30725185 | Comparative efficacy and safety of 15 and 30 mg upadacitinib administered to patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials. | 2020 Feb |
1 |
| 31 |
31378969 | Effects of Upadacitinib Coadministration on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates: A Study With the Modified Cooperstown 5+1 Cocktail. | 2020 Jan |
1 |
| 32 |
31448433 | Preferential Inhibition of JAK1 Relative to JAK3 by Upadacitinib: Exposure-Response Analyses of Ex Vivo Data From 2 Phase 1 Clinical Trials and Comparison to Tofacitinib. | 2020 Feb |
4 |
| 33 |
31701537 | Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects With Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, or Atopic Dermatitis: Population Analyses of Phase 1 and 2 Clinical Trials. | 2020 Apr |
1 |
| 34 |
31786154 | Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. | 2020 Mar |
1 |
| 35 |
31867699 | Clinical Pharmacokinetics of Upadacitinib: Review of Data Relevant to the Rheumatoid Arthritis Indication. | 2020 May |
1 |
| 36 |
32092309 | Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis. | 2020 Jun |
1 |
| 37 |
32515665 | Evaluating upadacitinib for the treatment of rheumatoid arthritis. | 2020 Sep |
2 |
| 38 |
32530345 | A review of upadacitinib in rheumatoid arthritis. | 2020 Sep |
1 |
| 39 |
32776305 | Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib. | 2020 Dec |
2 |
| 40 |
33193430 | Impact of Janus Kinase Inhibition on the Treatment of Axial Spondyloarthropathies. | 2020 |
1 |
| 41 |
33332480 | Upadacitinib tartrate in rheumatoid arthritis. | 2020 Nov |
1 |
| 42 |
30394138 | Upadacitinib for the treatment of rheumatoid arthritis. | 2019 Jan |
3 |
| 43 |
30500075 | The JAK1 Inhibitor Upadacitinib Has No Effect on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol: A Study in Healthy Female Subjects. | 2019 Apr |
2 |
| 44 |
30633369 | Characterization of the Effect of Renal Impairment on Upadacitinib Pharmacokinetics. | 2019 Jun |
1 |
| 45 |
30945116 | Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I-III Clinical Trials. | 2019 Aug |
1 |
| 46 |
30973649 | Characterization of the Effect of Hepatic Impairment on Upadacitinib Pharmacokinetics. | 2019 Sep |
1 |
| 47 |
31130260 | Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. | 2019 Jun 8 |
1 |
| 48 |
31287230 | Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial. | 2019 Nov |
1 |
| 49 |
31317509 | Innovations in Oral Therapies for Inflammatory Bowel Disease. | 2019 Aug |
1 |
| 50 |
31327403 | Pharmacology, efficacy and safety of JAK inhibitors in Crohn's disease. | 2019 Feb - Apr |
1 |